CABP2 and hearing loss disorder: Evaluation of known genes associated with isolated hearing loss yielded a short list that included CABP2 among the best suited genes amenable for gene therapy, particularly due to preservation of cochlear architecture after P28, small gene size (human RNA size is 660 bp) allowing transgene packaging into a single AAV, and expression in hair cells [78].